Multiple soluble and cellular pathways

The term Multiple soluble and cellular pathways does not refer to a single molecular target, such as a specific receptor or enzyme, but is instead a descriptive category used in pharmacology and clinical research. It characterizes interventions that exert pleiotropic effects by simultaneously modulating a wide array of signaling cascades, secreted factors, and cellular interactions (Source: ClinicalTrials.gov; Nature Chemical Biology, 2008, 4(11):682-690). This broad approach is often associated with complex therapies like intravenous immunoglobulin (IVIG), therapeutic plasma exchange, or multi-target immunomodulatory drugs (IMiDs) used to treat systemic inflammatory or autoimmune conditions. Because the term encompasses a vast network of biological processes—ranging from cytokine regulation to lymphocyte activation—it lacks the molecular specificity required for modern precision medicine (Source: Nature Reviews Drug Discovery, 2005, 4(1):71-78). While targeting multiple pathways can be advantageous in overcoming resistance in diseases like cancer or sepsis, it presents significant challenges in identifying specific efficacy biomarkers and predicting off-target adverse events. Consequently, in structured biochemical databases, this entry is typically regarded as a non-specific or collective designation rather than a discrete therapeutic target.

Other names

Pleiotropic pathwaysMulti-target signalingSystemic biological networksNetwork pharmacology targets

Simultaneous modulation of multiple extracellular soluble factors (such as cytokines and chemokines) and various intracellular signaling networks to achieve a systemic therapeutic effect.